Author: Jian Wang (王健), RAC
Vice President, Quality & Regulatory Affairs at VistaMed Technologies
As a certified Regulatory Affairs professional (RAC) with over 18 years of experience, Jian has personally led VistaMed's successful efforts to secure FDA 510(k) Clearance and the CE Mark under the stringent EU MDR 2017/745.
For a Regulatory Affairs Manager, an electrocardiogram monitor is not simply another Class II device. It is governed by a highly specific and complex web of harmonized IEC standards that demand deep scrutiny during any supplier qualification process. Your role requires you to look past the surface of a 510(k) letter and assess the true robustness of a manufacturer’s quality and compliance culture.
This guide provides the specific questions and expected answers that I use when conducting due diligence on a potential ECG device partner.
A VP of Quality & Regulatory's Guiding Principle
"Compliance isn't about having the right documents. It's about having the right data behind those documents. My job is to scrutinize that data, and that's the lens every RA professional should use when evaluating a new manufacturing partner. A thin technical file is a major red flag."
— Jian Wang (王健), RAC
The Shifting Standards Landscape: Old Mindset vs. New Reality
The transition to regulations like EU MDR has fundamentally changed what is expected of device manufacturers. A passive, check-the-box approach is no longer defensible.
|
Regulatory Expectation
|
Old Mindset (Passive Compliance)
|
New Mindset (Proactive Quality)
|
|
Clinical Evidence
|
Provide just enough data to prove "substantial equivalence" for 510(k).
|
Maintain a living clinical evaluation report (CER) with ongoing evidence generation.
|
|
Post-Market Surveillance
|
A reactive complaint-handling system.
|
A proactive Post-Market Clinical Follow-up (PMCF) strategy to continuously monitor real-world performance.
|
|
Risk Management
|
Risk file is updated only when necessary.
|
Risk management is integrated throughout the entire product lifecycle, from design to decommissioning.
|
|
Technical Documentation
|
A collection of documents to satisfy an auditor.
|
A well-organized, transparent, and readily available Technical File that tells a clear story of the device's safety and performance.
|
Your ECG Compliance Questions, Answered
1. Which specific IEC standards are non-negotiable for ECG monitors?
This is the foundational technical question. While many standards apply, two are paramount for ECGs, and a manufacturer must be able to provide a Declaration of Conformity for the relevant one. Both the FDA and European Notified Bodies reference these as part of their review process [citation: 1].
-
IEC 60601-2-25: This standard applies to the safety and performance of diagnostic electrocardiographs. It is the key standard for traditional, high-fidelity ECG machines [citation: 1][citation: 3].
-
IEC 60601-2-47: This standard covers performance and safety for ambulatory (wearable or portable) ECG systems, like Holter monitors or our ECG-6Portable [citation: 1].
Adherence to these standards is mandatory for achieving global regulatory compliance, including both FDA clearance and the CE Mark under MDR [citation: 1][citation: 2].
2. What kind of performance data should I request beyond basic accuracy specs?
Ask specifically for their test data on Baseline Wander (BLW) suppression. BLW is a low-frequency drift in the ECG signal caused by patient movement or respiration, and it is a persistent source of unreadable traces in real-world clinical use [citation: 1].
The IEC standards define the filtering requirements, but they don't specify how to implement them [citation: 1]. A superior manufacturer will have invested significant R&D into developing a real-time, morphology-preserving filter that works effectively on low-power devices. In my experience auditing technical files, I always ask for the test reports on a manufacturer's BLW suppression algorithm. A clean, stable trace under simulated motion conditions is the mark of a well-engineered device.
3. How does your company demonstrate a real commitment to Post-Market Clinical Follow-up (PMCF)?
Under EU MDR 2017/745, a PMCF plan is a mandatory part of the technical file. However, a plan is not the same as a demonstrated commitment. You should look for evidence that the manufacturer actively seeks out and generates real-world evidence on their products after they are on the market.
This is where a manufacturer's collaborative spirit becomes a key indicator of their quality culture. For instance, a proactive approach might involve a study like the one VistaMed participated in with the Cardiovascular Research Institute at Stanford University. While that specific remote monitoring trial used our SmartBP-Connect device, it serves as a powerful example of our methodology: collaborating with world-class academic institutions to produce peer-reviewed data published in journals like the Journal of Telemedicine and Telecare. This type of activity is a gold-standard example of PMCF in action. It demonstrates a commitment to transparency and evidence that goes far beyond the minimum regulatory requirement.
Finding a manufacturing partner who views rigorous compliance not as a burden, but as a core component of their engineering philosophy, is the ultimate goal of regulatory due diligence. This is how you secure a reliable product and a low-risk partner for your institution.
About the Author
Jian Wang (王健), RAC serves as Vice President, Quality & Regulatory Affairs at VistaMed Technologies. As a certified Regulatory Affairs professional (RAC) with over 18 years of experience, he masterfully navigates the complex landscape of international medical device regulations. Jian has personally led the efforts for VistaMed to secure and maintain critical certifications, including FDA 510(k) Clearance, CE Mark under EU MDR 2017/745, and the ISO 13485:2016 quality management system certification (BSI Certificate No. FS 738429). This article draws from his extensive experience in auditing the technical files and quality systems of medical device manufacturers worldwide.
Medical Disclaimer：The information provided is for informational purposes and intended for a B2B audience of healthcare professionals and procurement decision-makers. It is not a substitute for professional medical or financial advice. TCO and ROI results may vary based on facility size, usage patterns, and local market conditions. All certifications and regulatory clearances referenced are accurate as of the date of publication. Please contact VistaMed Technologies for the most current documentation.
EN
